CAMBRIDGE, Mass.–Obsidian Therapeutics reported encouraging clinical results for its experimental melanoma cell therapy, amsoki-cel, while ending the third quarter of 2026 with $324.4 million in cash, cash equivalents and marketable securities following a major financing and its debut on the Nasdaq stock exchange.
The biotechnology company reported a net loss of $50.7 million, or $1.23 per share, for the quarter ended September 30, 2026, as it continued advancing clinical development of its lead cancer treatment.
Obsidian said its available financial resources are expected to support planned operations into the second half of 2028.
The company’s primary development program, amsokigene autoleucel (amsoki-cel), is an investigational engineered tumor-infiltrating lymphocyte (TIL) therapy designed to treat patients with advanced melanoma and other solid tumors.
Updated results presented at the Society for Immunotherapy of Cancer’s 2026 Annual Meeting showed an objective response rate of 67% among 15 patients with advanced melanoma who received the recommended Phase 2 dose of amsoki-cel.
The patients had previously developed resistance to immune checkpoint inhibitors, a class of cancer treatments that helps the immune system recognize and attack tumors.
Of the 15 patients evaluated, two achieved confirmed complete responses, meaning no detectable cancer remained under the study’s response criteria, while eight experienced confirmed partial responses.
Two patients with partial responses demonstrated a 100% reduction in the combined measurements of their target lesions.
The median progression-free survival was 8.3 months, while the median duration of response had not been reached after a median follow-up of 14.3 months.
Five of the 10 patients who responded to treatment continued to demonstrate responses at the time of the analysis. Five of the 15 treated patients also maintained deep responses at the 12-month follow-up point.
The findings came from the ongoing Phase 1/2 Agni-01 clinical trial, which is evaluating amsoki-cel in patients with advanced or metastatic melanoma whose disease has progressed despite previous immunotherapy.
“2026 has been a transformative year so far for Obsidian. In the third quarter, we closed an oversubscribed $350 million financing, completed our transaction with Galera Therapeutics, and debuted on Nasdaq as a publicly traded company,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidian. “We have made substantial progress advancing amsoki-cel, with enrollment ongoing in the registration-enabling immune checkpoint inhibitor-resistant advanced melanoma cohort of our Agni-01 study. The updated data we presented at SITC further strengthen our belief in the program, highlighting amsoki-cel’s consistent, favorable safety profile and encouraging clinical activity in patients with advanced melanoma, including an objective response rate of 67%, median progression-free survival of 8.3 months, and median duration of response not yet reached at median study follow-up of 14.3 months. We remain on track to complete enrollment in the registration-enabling cohort by the end of the first quarter of 2027 and report topline data by year-end 2027.”
The company also presented pooled safety findings involving 37 patients treated across its initial Phase 1 study and the ongoing Agni-01 trial.
Researchers reported no dose-limiting toxicities, treatment-related deaths, immune effector cell-associated neurotoxicity syndrome or transfers to intensive care units.
Most commonly reported non-hematologic adverse events were mild or moderate, although one patient experienced Grade 3 cytokine release syndrome, a potentially serious inflammatory reaction associated with certain immune cell therapies.
The updated results provide preliminary evidence of the treatment’s potential, although the relatively small number of patients and the absence of a randomized comparison group mean larger studies will be needed to establish its effectiveness.
Amsoki-cel uses a patient’s own tumor-infiltrating lymphocytes, immune cells capable of recognizing cancer, which are collected, genetically engineered and expanded before being administered back to the patient.
The treatment incorporates Obsidian’s proprietary cytoDRiVE technology, which is designed to regulate the activity of engineered proteins using approved small-molecule drugs.
In the case of amsoki-cel, the technology controls a modified form of interleukin-15, a protein involved in supporting immune cell activity.
Obsidian is currently enrolling patients in a registration-enabling cohort of the Agni-01 study, which is intended to generate additional evidence supporting potential regulatory approval.
The company expects to complete enrollment by the end of the first quarter of 2027 and report topline results before the end of that year.
Amsoki-cel is also being evaluated in patients with non-small cell lung cancer, with initial Phase 1 data expected during the first half of 2027.
Obsidian’s clinical progress follows several significant corporate developments during the third quarter.
The company completed its transaction with Galera Therapeutics and began trading on Nasdaq under the ticker symbol OBX on August 4, 2026.
It also completed a previously announced private placement that generated $350 million in gross proceeds, providing additional capital to support its clinical programs.
Research and development expenses totaled $27.5 million during the third quarter, while general and administrative expenses reached $10.3 million.
The company also recorded $15.1 million in acquired in-process research and development expenses associated with the Galera transaction.
In November, Obsidian appointed Mark Reisenauer to its Board of Directors, adding an executive with more than three decades of experience in oncology commercialization and pharmaceutical leadership.
Reisenauer most recently served as CEO and a Director of Assertio, which was acquired by Zydus Lifesciences. He previously served as President of U.S. Commercial at Astellas Pharmaceuticals and held senior leadership positions at Micromet and Abbott Laboratories.
Obsidian also announced the publication of clinical findings involving amsoki-cel in the medical journal Nature Medicine, detailing safety and efficacy results from its early-stage trials.
The company, which maintains offices in Cambridge and Bedford, Massachusetts, is continuing to focus its resources on advancing engineered cell therapies for patients with solid tumors.
Its next major clinical milestones include additional lung cancer data and the completion of enrollment in the melanoma registration-enabling study, followed by anticipated results in late 2027.


